CAREDX, INC. Cost of Revenue
CAREDX, INC. (CDNA) reported Cost of Revenue of $15.03 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-04.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2020-08-04
- CAREDX, INC. cost of revenue for the quarter ending 2020-06-30 was $15.03M, a 30.52% increase year-over-year.
- CAREDX, INC. cost of revenue for the quarter ending 2020-03-31 was $12.39M, a 27.32% increase year-over-year.
- CAREDX, INC. cost of revenue for the quarter ending 2019-12-31 was $12.72M, a 21.00% increase year-over-year.
- CAREDX, INC. cost of revenue for the quarter ending 2019-09-30 was $11.49M, a 29.33% increase year-over-year.
- CAREDX, INC. cost of revenue for fiscal 2019 was $45.45M, a 37.80% increase from fiscal 2018.
- CAREDX, INC. cost of revenue for fiscal 2018 was $32.99M, a 54.35% increase from fiscal 2017.
- CAREDX, INC. cost of revenue for fiscal 2017 was $21.37M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2020-06-30 | $15.03M 10-Q · filed 2020-08-04 | $27.42M 10-Q · filed 2020-08-04 | $40.13M derived: sum of 3 quarters · filed 2020-08-04 | $51.63M derived: sum of 4 quarters · filed 2020-08-04 |
| 2020-03-31 | $12.39M 10-Q · filed 2020-04-30 | $25.11M derived: sum of 2 quarters · filed 2020-04-30 | $36.60M derived: sum of 3 quarters · filed 2020-04-30 | $48.11M derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-12-31 | $12.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $24.21M derived: sum of 2 quarters · filed 2020-02-28 | $35.72M derived: sum of 3 quarters · filed 2020-08-04 | $45.45M 10-K · filed 2020-02-28 |
| 2019-09-30 | $11.49M 10-Q · filed 2019-10-31 | $23.01M derived: sum of 2 quarters · filed 2020-08-04 | $32.74M 10-Q · filed 2019-10-31 | $43.25M derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-06-30 | $11.51M 10-Q · filed 2020-08-04 | $21.25M 10-Q · filed 2020-08-04 | $31.75M derived: sum of 3 quarters · filed 2020-08-04 | $40.64M derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-03-31 | $9.73M 10-Q · filed 2020-04-30 | $20.24M derived: sum of 2 quarters · filed 2020-04-30 | $29.13M derived: sum of 3 quarters · filed 2020-04-30 | $36.34M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | $10.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $19.40M derived: sum of 2 quarters · filed 2020-02-28 | $26.60M derived: sum of 3 quarters · filed 2020-02-28 | $32.99M 10-K · filed 2020-02-28 |
| 2018-09-30 | $8.89M 10-Q · filed 2019-10-31 | $16.09M derived: sum of 2 quarters · filed 2019-10-31 | $22.48M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $7.21M 10-Q · filed 2019-08-01 | $13.59M 10-Q · filed 2019-08-01 | ||
| 2017-12-31 | $21.37M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |